Antimicrobials · Aminoglycosides
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Tobramycin is an aminoglycoside that exerts its bactericidal effect by binding to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
The primary clinical utility of tobramycin is the treatment of severe Gram-negative infections, particularly those caused by Pseudomonas aeruginosa.
Tobramycin exhibits concentration-dependent killing and a significant post-antibiotic effect, allowing for once-daily dosing regimens.
The most significant dose-limiting toxicities of tobramycin are nephrotoxicity (acute tubular necrosis) and ototoxicity (vestibular and auditory).
Tobramycin-induced nephrotoxicity typically presents as non-oliguric acute kidney injury due to proximal tubular cell accumulation.
Therapeutic drug monitoring is mandatory for tobramycin to prevent toxicity, requiring measurement of both peak and trough serum concentrations.
Tobramycin is frequently used in cystic fibrosis patients as an inhaled formulation to manage chronic pulmonary colonization by *Pseudomonas*.
Vignette unlocked
A 24-year-old male with cystic fibrosis presents for a routine follow-up. He reports a recent increase in sputum production and a low-grade fever. Sputum culture grows Pseudomonas aeruginosa. The patient is started on intravenous tobramycin. On day 5 of therapy, his serum creatinine increases from 0.8 mg/dL to 1.4 mg/dL, and he complains of tinnitus and a sensation of vertigo.
Which mechanism best explains the patient's current clinical findings?
Accumulation of the drug in the proximal renal tubules and inner ear hair cells.
The patient is experiencing classic aminoglycoside toxicity (nephrotoxicity and ototoxicity), which is tested by Bet 4 and Bet 5 regarding the dose-limiting side effects of tobramycin.
Full handout
High yield triage
Classification
Aminoglycoside antibiotic; bactericidal protein synthesis inhibitor.
Indications
Pseudomonas aeruginosa infections, cystic fibrosis pulmonary exacerbations, and bacterial conjunctivitis.
Mechanism of Action
Binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Side Effects
Ototoxicity, nephrotoxicity, and neuromuscular blockade.
Contraindications / Monitoring
Myasthenia gravis; monitor serum trough levels and creatinine.
Full handout
Mechanism of Action
Tobramycin irreversibly binds to the 30S ribosomal subunit, disrupting the initiation complex. This leads to the production of non-functional proteins and cell death. It is highly effective against aerobic gram-negative bacilli, specifically targeting the Pseudomonas species. The drug exhibits concentration-dependent killing and a significant post-antibiotic effect.
Unique Properties
Compared to gentamicin, tobramycin demonstrates superior activity against Pseudomonas aeruginosa. It is frequently utilized in inhaled formulations for chronic pulmonary management in patients with cystic fibrosis. It remains a cornerstone for systemic gram-negative coverage in severe sepsis.
Indications
Systemic administration is indicated for severe sepsis, pyelonephritis, and pneumonia caused by susceptible gram-negative organisms. Ophthalmic solutions are the first-line treatment for bacterial conjunctivitis. Inhaled tobramycin is used to suppress chronic Pseudomonas colonization in cystic fibrosis patients.
Pharmacokinetics
Tobramycin is poorly absorbed orally and must be administered parenterally for systemic infections. It is primarily excreted via glomerular filtration in the kidneys. Because it is hydrophilic, it has a low volume of distribution and does not penetrate the blood-brain barrier effectively.
Side Effects & Adverse Events
The most feared adverse effects are nephrotoxicity (acute tubular necrosis) and ototoxicity (vestibular and auditory damage). Neuromuscular blockade can occur, particularly in patients with underlying muscle weakness. Ototoxicity is often irreversible and may present as tinnitus or vertigo.
Contraindications
Myasthenia gravis is an absolute contraindication due to the risk of precipitating a crisis. Use with extreme caution in patients with pre-existing renal impairment, as drug accumulation rapidly increases toxicity. Avoid concurrent use with other nephrotoxic agents like vancomycin or amphotericin B.
Monitoring
Clinicians must monitor serum trough levels to prevent accumulation and peak levels to ensure efficacy. Serum creatinine and BUN should be checked daily to assess renal function. If therapy exceeds 3 days, perform serial audiometry to detect early signs of hearing loss.
Clinical Pearls
On boards, look for the patient with cystic fibrosis presenting with increased sputum production; inhaled tobramycin is the classic answer. Always remember the synergistic effect when combined with a beta-lactam for severe Pseudomonas infections. If a patient develops tinnitus while on this drug, the trough level is likely too high.